Abstract
THE number and diversity of the viruses which infect the upper respiratory tract, and cause the common cold, virtually preclude the control of this disease by conventional vaccines. From this, apart from symptomatic therapy, the only hope for effective treatment of this most prevalent of diseases is in the development of broad spectrum antiviral drugs. We have developed a substituted guanidine, ICI 65,709 (ref. 1) (Fig. 1) which has good activity in vitro against all twenty-five rhinovirus serotypes tested in human embryonic lung cells, and also against certain other picornaviruses.
Similar content being viewed by others
Article PDF
References
U.K. Patent No. 1,291,994.
Bucknall, R. A., J. gen. Virol., 1, 55 (1967).
Bucknall, R. A., Advances in Pharmacology and Chemotherapy (Academic Press, New York, 1973).
Rightsel, W. A., Dice, J. R., McAlpine, J. R., Timm, E. A., McLean, I. W., Dixon, G. J., and Schabel, F. M., Science, N.Y., 134, 558 (1961).
Melnick, J. L., Crowther, D., and Barrera-oro, J., Science, N.Y., 134, 557 (1961).
Dintner, Z., and Bengtsson, S., Virology, 24, 254 (1964).
Philipson, L., Bengtsson, S., and Dintner, Z., Virology, 29, 317 (1966).
Loddo, B., Gessa, G. L., Schvo, M. L., Spanedda, A., Brotzu, G., and Ferrari, W., Virology, 28, 707 (1966).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
BUCKNALL, R., SWALLOW, D., MOORES, H. et al. A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses. Nature 246, 144–145 (1973). https://doi.org/10.1038/246144a0
Received:
Issue Date:
DOI: https://doi.org/10.1038/246144a0
This article is cited by
-
Replication of rhinoviruses
Archives of Virology (1976)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.